A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation

被引：0

作者：

Lenz, Heinz-Josef

Ahn, Daniel H.

Ridinger, Maya

Erlander, Mark G.

Barzi, Afsaneh

机构：

[1] Univ Southern Calif, Los Angeles, CA 90007 USA

[2] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA

[3] Richard J Solove Res Inst, Columbus, OH USA

[4] Trovagene, San Diego, CA USA

[5] Trovagene, Carlsbad, CA USA

[6] Norris Comprehens Canc Ctr, USC Keck Sch Med, Los Angeles, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS265

引用

页数：1